ADVERTISEMENT
Dr Gatti-Mays Discusses DESTINY-Breast03 Trial Results
Margaret Gatti-Mays, MD, MPH, The Ohio State University, discusses the DESTINY-Breast03 trial, a phase 2 trial that compared TDM1 and trastuzumab deruxtecan in 2L metastatic HER2-positive breast cancer, presented at the 2021 ESMO Congress.
Disclaimer: The views and opinions expressed are those of the author(s) and do not necessarily reflect the official policy or position of Oncology Learning Network or HMP Global, their employees, and affiliates. Any content provided by our bloggers or authors are of their opinion and are not intended to malign any religion, ethnic group, club, association, organization, company, individual, anyone, or anything.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement